Search research articles
Contact Us
Filters
Showing results (91-100 of 95) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 95 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2012
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group
Stefan Gröschel, Richard F Schlenk, Jan Engelmann, et al.
Blood
|
January 25, 2020
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Cecilia Carpio, Reda Bouabdallah, Loïc Ysebaert, et al.
Haematologica
|
January 2, 2008
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
Henk M Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, et al.
The New England Journal of Medicine
|
December 8, 2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J Druker, François Guilhot, Stephen G O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2010
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia
Sanne Lugthart, Stefan Gröschel, H Berna Beverloo, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 95) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 95 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2012
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group
Stefan Gröschel, Richard F Schlenk, Jan Engelmann, et al.
Blood
|
January 25, 2020
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Cecilia Carpio, Reda Bouabdallah, Loïc Ysebaert, et al.
Haematologica
|
January 2, 2008
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
Henk M Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, et al.
The New England Journal of Medicine
|
December 8, 2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J Druker, François Guilhot, Stephen G O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2010
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia
Sanne Lugthart, Stefan Gröschel, H Berna Beverloo, et al.
Page
of 10